AFX 3721
Alternative Names: AFX-3721Latest Information Update: 28 Apr 2025
At a glance
- Originator Afecta Pharmaceuticals; LEO Pharma
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action Interleukin 13 modulators; Interleukin 4 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Respiratory tract disorders
- Discontinued Atopic dermatitis
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in USA
- 26 Mar 2021 Discontinued - Preclinical for Atopic dermatitis in USA (Topical) before March 2021 (Afecta Pharmaceuticals' pipeline, March 2021)
- 26 Mar 2021 Preclinical trials in Respiratory tract disorders in USA (unspecified route) before March 2021 (Afecta Pharmaceuticals' pipeline, March 2021)